Partners
Partners

Partner 40 - Clearbridge BioMedics


 

 

Ali Asgar Bhagat, PhD

Chief Operating Officer

 

 

 

undefinedE-Mail

 

 

Clearbridge BioMedics

 

81 Science park Drive, The Chadwick 02-03

Singapore Science Park 1

Singapore

 

undefinedWebsite

CANCER-ID Team Clearbridge BioMedics

 

 

Jean-Philippe Aurel

Global Sales Channel Partners

jp@clearbridgebiomedics.com  

 

Zhang Xing Lai

Lead Technical Development Engineer

zhangxing(at)clearbridgebiomedics.com 

 

 

 

 

 

 

 

 

 

Company presentation

 

Clearbridge BioMedics is a clinical oncology company that enables non-invasive liquid biopsy using a label-free Circulating Tumour Cell (CTC) enrichment platform. It is a National University of Singapore (NUS) spin-off company committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX System, using the CTChip®, is based on innovative technology that effectively isolates intact and viable CTCs from patients’ blood. The system uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells to be used for cancer diagnosis and treatment monitoring. By enriching CTCs from standard blood samples, the platform allows for analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine.

Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011, and the ClearCell® FX attained CE IVD in 2015.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

CANCER-ID Workpackages

Search
Top
Home
Menu

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

EU logo
imi Logo
efpia Logo
EU Logo
IMI Logo
efpia Logo

News Section

FREE OF CHARGE hands-on digital PCR training course in Gothenburg, Sweden, on... Read more

Social Media

LinkedIn Cancer-ID